Arnold Nadel, Michael Drakopoulos, Harnaina K Bains, Avram Bar-Meir, Alessandro Marchese, Alice T Lyon, Rukhsana G Mirza
{"title":"Analysis of quantitative OCT and SS-OCTA metrics three months after initiation of intravitreal faricimab for treatment-recalcitrant neovascular AMD.","authors":"Arnold Nadel, Michael Drakopoulos, Harnaina K Bains, Avram Bar-Meir, Alessandro Marchese, Alice T Lyon, Rukhsana G Mirza","doi":"10.1038/s41433-024-03583-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer's recommended induction phase of treatment.</p><p><strong>Methods: </strong>Fifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months. Best-corrected visual acuity (BCVA), OCT, pigment epithelial detachment (PED), and macular neovascularization (MNV) parameters were analyzed at baseline and 3 months.</p><p><strong>Results: </strong>Thirty-two patients (38 eyes) were included in the baseline OCT characteristic analysis, 29 patients (35 eyes) in the MNV analysis, and 18 patients (21 eyes) in the PED analysis. Significant decreases in PED parameters were observed, including PED volume (mean decrease of 0.0592 mm<sup>3</sup> (-19.66%; p = 0.0164), sample standard deviation (ssd) = 0.114 mm<sup>3</sup>), mean height (mean decrease of 0.00871 mm (-19.16%; p = 0.0003), ssd = 0.0143 mm), and maximum height (mean decrease of 0.0242 mm (-15.28%; p = 0.002), ssd = 0.0359). Significant decreases in MNV metrics were also observed, including area (mean decrease of 0.252 mm<sup>2</sup> (-9.06%; p = 0.0054), ssd = 0.519 mm<sup>2</sup>), and vessel area density (mean decrease of 6.51% absolute (-8.23%; p = 0.0004), ssd = 0.0943% absolute). BCVA (logMAR) remained stable between baseline and 3 months (0.25-0.23; p = 0.34). Notably, there were no statistically significant changes in the percentage of eyes with intraretinal fluid (IRF) or subretinal fluid (SRF) between baseline and 3 months (all p > 0.05).</p><p><strong>Conclusions: </strong>In recalcitrant nAMD patients who were transitioned to faricimab, patients maintained their vision while significant improvements in OCT PED and SS-OCTA MNV parameters were seen during the induction phase.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03583-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer's recommended induction phase of treatment.
Methods: Fifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months. Best-corrected visual acuity (BCVA), OCT, pigment epithelial detachment (PED), and macular neovascularization (MNV) parameters were analyzed at baseline and 3 months.
Results: Thirty-two patients (38 eyes) were included in the baseline OCT characteristic analysis, 29 patients (35 eyes) in the MNV analysis, and 18 patients (21 eyes) in the PED analysis. Significant decreases in PED parameters were observed, including PED volume (mean decrease of 0.0592 mm3 (-19.66%; p = 0.0164), sample standard deviation (ssd) = 0.114 mm3), mean height (mean decrease of 0.00871 mm (-19.16%; p = 0.0003), ssd = 0.0143 mm), and maximum height (mean decrease of 0.0242 mm (-15.28%; p = 0.002), ssd = 0.0359). Significant decreases in MNV metrics were also observed, including area (mean decrease of 0.252 mm2 (-9.06%; p = 0.0054), ssd = 0.519 mm2), and vessel area density (mean decrease of 6.51% absolute (-8.23%; p = 0.0004), ssd = 0.0943% absolute). BCVA (logMAR) remained stable between baseline and 3 months (0.25-0.23; p = 0.34). Notably, there were no statistically significant changes in the percentage of eyes with intraretinal fluid (IRF) or subretinal fluid (SRF) between baseline and 3 months (all p > 0.05).
Conclusions: In recalcitrant nAMD patients who were transitioned to faricimab, patients maintained their vision while significant improvements in OCT PED and SS-OCTA MNV parameters were seen during the induction phase.
期刊介绍：
Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists.
Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
